Illumina CEO Jay Flatley tells Xconomy's Luke Timmerman that for a long time there was no innovation in the industry until the advent of next-gen sequencing which caused "huge amount of money" to be invested in the space. Currently, Flatley considers Life Technologies to be Illumina's primary competitor, but says his company is "way ahead" in terms of market share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.

The New York Times reports on the shifting interpretations of what some genetic variants mean over time.

In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.

MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.